DETAILED ACTION
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
2. Applicant's preliminary amendment filed on 03/18/2024 is acknowledged.
Claims 40-54 are pending.
3. 35 U.S.C. § 101 reads as follows:
"Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title".
4. Claim 40-54 rejected under 35 U.S.C. 101 because the claimed invention is directed to judicial exceptions, i.e. an abstract idea and a law of nature, without significantly more.
The claims recite mental processes of “distinguishing,” comparing (“amount that is lower than a control value”), and reaching a conclusion (“”value is indicative of”). If a claim limitation covers performance of the limitation in the mind, then it falls within the “Mental Processes” grouping of abstract ideas. Accordingly, the claim recites an abstract idea.
The claims also recite a law of nature or a natural phenomenon, i.e. a naturally occurring correlation between circulating PD-L1 amount and the state of autoimmune disease.
The claims do not integrate the abstract idea or law of nature into a practical application because the claims are directed to a method of “distinguishing” between states of autoimmune disease, which is not a practical application.
The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception. The step of “determining the amount of circulating PD-L1 in a blood sample obtained from the human subject by contacting the blood sample with a detectably labeled antibody specific for PD-L1” is a data gathering step required to use the naturally occurring correlation does not add a meaningful limitation to the method because it is well-understood, routine, and conventional. Therefore, this step is not sufficient to amount to significantly more than the judicial exception. Consequently, the claims are not patent eligible.
5. The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
6. Claims 41-54 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention.
(i) Claim 40 is indefinite in the recitation of a “control value” of circulating PD-L1, because the value is unknown.
(ii) Claim 45 is indefinite, because it is unknown how the recited additional step of “contacting” relates to “distinguishing” the states of autoimmune disease.
(iii) Claim 48 is indefinite, because the recitation of “the APC” lacks proper antecedent basis in the base claim.
(iv) Claim 51 is indefinite, because it is unknown how the control value is “established based on” the PD-L1 level of one or more healthy subjects.
(v) Claims 42-54 are indefinite, because they encompass the indefinite limitations of the claim(s) on which they depend.
In view of the above, a person of ordinary skill in the art cannot unequivocally interpret the metes and bounds of the claims so as to understand how to avoid infringement. Applicant is reminded that any amendment must point to a basis in the specification so as not to add New Matter. See MPEP 714.02 and 2163.06.
7. The following is a quotation of 35 U.S.C. 112(d):
REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
8. Claim 41 is rejected under 35 U.S.C. 112(d) as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Claim 41 depends on claim 40 which is limited to autoimmune disease, whereas claim 41 encompasses transplant rejection which is not an autoimmune disease. Therefore, dependent claim 41 may be infringed without infringing the base claim, and as such, claim 41 fails to further limit, and fails to include all the limitations of the claim upon which it depends.
Applicant may cancel the claim, amend the claim to place it in proper dependent form, rewrite the claim in independent form, or present a sufficient showing that the dependent claim complies with the statutory requirements.
9. The following US Patents share a coinventor and/or an assignee with the present application, and claim subject matter similar to that of the present claims, but do not contain patented claims which would anticipate or make obvious the presently claimed invention:
US 8062852 (IDS),
US 9168296 (IDS),
US 10371702,
US 11860161.
10. Conclusion: no claim is allowed.
11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ILIA I OUSPENSKI whose telephone number is (571)272-2920. The examiner can normally be reached 9 AM - 5:30 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ILIA I OUSPENSKI/ Primary Examiner, Art Unit 1644